MS41
Based on 1 Customer Validation
MS41 is a ENL PROTAC degrader with a DC50 of 3.50 nM. MS41 recruits the VHL E3 ubiquitin ligase, triggers ENL degradation via the ubiquitin-proteasome system, and simultaneously induces AF9 degradation. MS41 reduces the chromatin occupancy of ENL-associated transcription elongation complexes, suppresses oncogene expression, and activates differentiation gene expression. MS41 inhibits leukemia cell growth and induces cell cycle arrest and apoptosis. MS41 inhibits leukemia progression in xenograft mouse models. MS41 can be used for research on mixed lineage leukemia-rearranged leukemia and nephroblastoma.
(Pink: ENL ligand (HY-169094); Blue: VHL ligand (HY-112078); Black: linker (HY-W105744)).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98.97%
- CAS 番号: 2768610-97-3
- 分子式: C56H70N8O9S
- 分子量:1031.27
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
PROTACs アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
IC50 & Target
|
VHL |
ENL 2.84 nM (DC50) |
体外実験
MS41 (0.1 nM-54 μM; 1 hour) potently inhibits the ENL YEATS domain-H3K9ac interaction with an IC50 of 119.43 nM, binds comparably to AF9 YEATS domain, and does not bind GAS41 or YEATS2 YEATS domains[1].
MS41 (0.25-256 nM; 24 hours) potently, rapidly, and reversibly degrades ENL in MV4;11 cells via a VHL- and ubiquitin-proteasome system-dependent mechanism, with a DC50 of 3.50 nM and >99% maximal degradation[1].
MS41 (0.25-256 nM; 24 hours) potently and rapidly degrades ENL in SEMK2, Jurkat, and KASUMI1 human leukemia cells, with DC50 values ranging from 2.84 to 26.58 nM and >93% maximal degradation[1].
MS41 is a highly selective ENL degrader in MV4;11 cells, with no detectable off-target protein degradation at the proteome-wide level[1].
MS41 (6 days, 12 days for Jurkat and K-562) potently inhibits proliferation of ENL-dependent human leukemia cell lines (MV4;11, RS4;11, SEMK2, KASUMI1) with GI50 values ranging from 21.28 to 406.46 nM, while having no effect on non-ENL-dependent Jurkat and K-562 cells[1].
MS41 (100 nM; 7-10 days) impairs the clonogenic potential of ENL-dependent human leukemia cell lines MV4;11, SEMK2, and KASUMI1, but not non-ENL-dependent Jurkat cells[1].
MS41 (10-300 nM; 24 h) suppresses ENL-dependent oncogenic gene expression programs in MV4;11 cells, down-regulating key leukemia-associated genes and up-regulating myeloid differentiation markers, with effects matching those of ENL knockout[1].
MS41 (100 nM; 6, 24 hours) reduces chromatin occupancy of ENL and its associated transcription elongation machinery (SEC, DOT1L, elongating Pol II) on target genes, leading to suppressed gene expression in MV4;11 cells[1].
MS41 (1-1000 nM; 24, 72 hours) potently degrades wild-type and YEATS domain mutant ENL proteins and suppresses the aberrant HOXA gene expression induced by mutant ENL in HEK293 cells[1].
MS41 (100 nM; 24-72 hours) induces time-dependent G1 cell cycle arrest and apoptosis in MV4;11 human leukemia cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human MLL-r leukemia cell line MV4;11
-
Concentration:0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 nM (24-hour treatment)
100 nM (washout and mechanism validation)
0, 0.2, 1, 5 μM PFI-6 (HY-155412), VH298 (HY-100947), MG132 (HY-13259) (pretreatment)
0, 0.1, 0.3, 1 μM MLN4924 (HY-70062) (pretreatment) -
Incubation Time:24 hours (concentration-dependent degradation)
0.5, 1, 2, 6, 12, 24, 48, 72 hours (washout)
2 hours (MS41 treatment with 1-hour pretreatment) -
Result:Induced concentration-dependent ENL degradation with a DC50 of 3.50 nM and Dmax of 99.8%.
Induced rapid ENL degradation detected as early as 30 minutes, maximal at 6 hours with 100 nM MS41.
Restored ENL levels by 6 hours and fully restored by 12 hours after washout.
Blocked MS41-mediated ENL degradation in a concentration-dependent manner with pretreatment of PFI-6, VH298, MG132, or MLN4924.
Completely abolished MS41-induced ENL degradation with CRISPR-Cas9-mediated VHL ablation.
-
Cell Line:human leukemia cell lines SEMK2, Jurkat, KASUMI1
-
Concentration:0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256 nM (24-hour treatment)
100 nM (time-course) -
Incubation Time:24 hours (concentration-dependent degradation)
0.5, 1, 2, 6, 12, 24, 48, 72 hours (time-course) -
Result:Induced concentration-dependent ENL degradation with DC50 values of 2.84 nM (SEMK2), 3.03 nM (Jurkat), and 26.58 nM (KASUMI1), with Dmax > 93% across all cell lines.
Induced rapid ENL degradation detected as early as 30 minutes, maximal at 6 hours with 100 nM MS41.
-
Cell Line:human MLL-r leukemia cell line MV4;11
-
Concentration:100 nM
-
Incubation Time:24, 48, 72 h
-
Result:Induced G1 cell cycle arrest in a time-dependent manner, with significant increases in G1-phase cells at 48 and 72 hours.
Increased late apoptosis, with significant increases at 48 and 72 hours.
Showed no such effects with MS41N and PFI-6.
-
Cell Line:human MLL-r leukemia cell line MV4;11
-
Concentration:100 nM
-
Incubation Time:24, 48, 72 h
-
Result:Induced time-dependent apoptosis in MV4;11 human leukemia cells.
-
Cell Line:human MLL-r leukemia cell line MV4;11
-
Concentration:10, 30, 100, 300 nM
-
Incubation Time:24 h
-
Result:Suppressed ENL-dependent oncogenic gene expression programs in MV4;11 cells, down-regulating key leukemia-associated genes and up-regulating myeloid differentiation markers.
-
Cell Line:human MLL-r leukemia cell line MV4;11
-
Concentration:100 nM
-
Incubation Time:6, 24 hours
-
Result:Reduced chromatin occupancy of ENL and its associated transcription elongation machinery (SEC, DOT1L, elongating Pol II) on target genes, leading to suppressed gene expression in MV4;11 cells.
-
Cell Line:HEK293 cells
-
Concentration:100 nM
-
Incubation Time:72 h
-
Result:Suppressed the aberrant HOXA gene expression induced by mutant ENL in HEK293 cells.
Parmacokinetics
| Species | Dose | Route | Cmax | Plasma Concentration |
|---|---|---|---|---|
| Mice[1] | 50 mg/kg | i.p. | 241.8 nM | >30 nM |
体内実験
MS41 (50 mg/kg; i.p.; once daily; 30 consecutive days) exhibits no detectable in vivo toxicity in healthy C57BL/6J mice, with only mild, reversible effects on normal hematopoiesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.Cg-Prkdcscid Il2rgtm.Wjl/SzJ (NSG) (6 to 8 weeks old, sublethally irradiated, transplanted with luciferase/turboGFP-expressing MV4;11 cells via tail vein injection)[1]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily; starting 10 days post-transplant until study endpoint
-
Result:Prolonged median survival to 49.5 days compared to 37 days for vehicle controls.
Reduced percentages of human CD45+ leukemia cells in peripheral blood.
Drastically reduced bioluminescent signals (leukemia burden).
Showed minimal leukemia cell infiltration in bone marrow, liver, and spleen compared to extensive infiltration in vehicle controls.
Reduced proliferation of leukemia cells confirmed by Ki-67 staining.
Induced complete ENL degradation in bone marrow leukemia cells.
化学情報
-
CAS 番号 2768610-97-3
-
性状 Solid
-
分子量 1031.27
-
分子式 C56H70N8O9S
-
Color White to off-white
-
SMILES
CC1=C(SC=N1)C2=CC=C(C=C2)[C@@H](NC([C@@H]3C[C@H](CN3C([C@H](C(C)(C)C)NC(CCCCCCCCCNC(C4=CC=C5CC[C@H](C5=C4)NC(C6=NOC(C7=CC(O)=C(C=C7)C(N(C)C)=O)=C6)=O)=O)=O)=O)O)=O)C
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
体外:
DMSO : 100 mg/mL (96.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
プロトコル
-
RT-PCR
Reverse transcription technology uses RNA as a template to synthesize DNA. RT-PCR is simple, specific and sensitive, and can be used to detect gene expression levels and expression differences in cells; detect RNA virus content; clone cDNA sequences of specific genes.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Real Time qPCR (Q-PCR)
Real-time quantitative PCR (qPCR) quantifies an amplifiable nucleic-acid target by monitoring fluorescence during PCR cycling rather than measuring product only after amplification. The increase in fluorescence tracks accumulation of PCR product, and the quantification cycle (Cq; historically also Ct/CP) is related to the initial amount of target: samples containing more starting target generally reach the defined fluorescence threshold in fewer cycles.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
純度とドキュメンテーション
-
データシート (283 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9697 mL | 4.8484 mL | 9.6968 mL | 24.2420 mL |
| 5 mM | 0.1939 mL | 0.9697 mL | 1.9394 mL | 4.8484 mL | |
| 10 mM | 0.0970 mL | 0.4848 mL | 0.9697 mL | 2.4242 mL | |
| 15 mM | 0.0646 mL | 0.3232 mL | 0.6465 mL | 1.6161 mL | |
| 20 mM | 0.0485 mL | 0.2424 mL | 0.4848 mL | 1.2121 mL | |
| 25 mM | 0.0388 mL | 0.1939 mL | 0.3879 mL | 0.9697 mL | |
| 30 mM | 0.0323 mL | 0.1616 mL | 0.3232 mL | 0.8081 mL | |
| 40 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.6060 mL | |
| 50 mM | 0.0194 mL | 0.0970 mL | 0.1939 mL | 0.4848 mL | |
| 60 mM | 0.0162 mL | 0.0808 mL | 0.1616 mL | 0.4040 mL | |
| 80 mM | 0.0121 mL | 0.0606 mL | 0.1212 mL | 0.3030 mL |